In the absence of a recognized gold standard for salvage and even upfront treatment for T-NHL (4, 31), we identified fotemustine, as a possible therapeutic option for our patients, owing to its pharmacodynamic advantages over other nitrosoureas (16–18), the low expression of AGT and MGMT in T-cell tumors (20, 21), and its favorable toxicity profile in pretreated patients (32). The gene discussed is MGMT; the disease is non-Hodgkin lymphoma.